A major breakthrough in the fight against Amyotrophic Lateral Sclerosis (ALS) comes from an international study coordinated by Professor Adriano Chiò, Director of University Neurology 1 at the City of Health in Turin, and Professor Andrea Calvo, in collaboration with the U.S. National Institutes of Health (NIH). The findings were published in the journal Nature Medicine. The researchers identified a group of proteins in the blood that could serve as a reliable biomarker, allowing them to identify the disease in its early stages. The discovery was due to the use of Olink Explore 3072 advanced proteomics technology, which is capable of measuring with extreme precision the concentration of more than 3,000 proteins in plasma. “For the first time,” Chiò explained, "we have a potential tool not only to improve and accelerate the diagnosis of ALS, but also to recognize it very early, allowing faster and more targeted interventions.